Companies With First ever concalls OR Investor Presentations

[Anirudhmadhwa_Kavili]

Aarti Pharma Labs:

Aarti Pharma Labs

Aarti Pharmalabs Q1 concall highlights - Sales - 458 vs 457 cr EBITDA - 85 vs 86 cr ( margins flat at 19 pc ) PAT - 47 vs 52 cr (due higher depreciation and tax rate) Manufacturing footprint - Dombivali - Unit-1, APIs and Intermediates Vapi - Unit-2, Api, intermediates, custom synthesis Tarapur - Unit 3- Xanthine derivatives Unit 4- APIs Unit-5 - Xanthine unit Atali - New unit under construction Vapi- R&D center Sales breakup- Xanthine -56 pc API + Intermediates - 37 pc CMO/CDMO …

Aarti Pharmalabs.pdf (730.3 KB)